{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:52:57Z","timestamp":1776880377765,"version":"3.51.2"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijtb.2025.07.006","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:01:59Z","timestamp":1752678119000},"page":"218-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rifampicin population pharmacokinetics and pharmacogenomic evaluation of SLCO1B1 gene in tuberculosis patients"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2530-599X","authenticated-orcid":false,"given":"Avinash","family":"Lomash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vandana","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Shariq","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwani","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mradul Kumar","family":"Daga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2025.07.006_bib1","unstructured":"World Health Organization. Global Tuberculosis Report. 2019th ed."},{"issue":"1","key":"10.1016\/j.ijtb.2025.07.006_bib2","first-page":"1","article-title":"Recent changes in technical and operational guidelines for tuberculosis control programme in India - 2016: a paradigm shift in tuberculosis control","volume":"5","author":"Chaudhuri","year":"2017","journal-title":"J Assoc Chest Phys"},{"key":"10.1016\/j.ijtb.2025.07.006_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-7-19","article-title":"Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis","volume":"7","author":"Schaaf","year":"2009","journal-title":"BMC Med"},{"key":"10.1016\/j.ijtb.2025.07.006_bib4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.5588\/ijtld.13.0819","article-title":"Rifampicin pharmacokinetics in children under the revised national tuberculosis control programme, India, 2009","volume":"19","author":"Arya","year":"2015","journal-title":"Int J Tubercul Lung Dis"},{"issue":"8","key":"10.1016\/j.ijtb.2025.07.006_bib5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3855\/jidc.4696","article-title":"Low rifampicin concentrations in tuberculosis patients with HIV infection","volume":"8","author":"Gengiah","year":"2014","journal-title":"J Infect Dev Ctries"},{"issue":"9","key":"10.1016\/j.ijtb.2025.07.006_bib6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2217\/pgs-2017-0176","article-title":"Role of Vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics","volume":"18","author":"Allegra","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.ijtb.2025.07.006_bib7","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.5588\/ijtld.15.1007","article-title":"SLCO1B1 gene polymorphisms do not influence plasma rifampicin concentrations in a South Indian population","volume":"20","author":"Ramesh","year":"2016","journal-title":"Int J Tubercul Lung Dis"},{"issue":"3","key":"10.1016\/j.ijtb.2025.07.006_bib8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"10","key":"10.1016\/j.ijtb.2025.07.006_bib9","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1128\/AAC.00353-10","article-title":"Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations","volume":"54","author":"Weiner","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijtb.2025.07.006_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/tpj.2009.54","article-title":"The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy","volume":"10","author":"Romaine","year":"2010","journal-title":"Pharmacogenomics J"},{"issue":"38","key":"10.1016\/j.ijtb.2025.07.006_bib11","doi-asserted-by":"crossref","first-page":"35669","DOI":"10.1074\/jbc.M103792200","article-title":"Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans","volume":"276","author":"Tirona","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ijtb.2025.07.006_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FPC.0000000000000018","article-title":"The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study","volume":"24","author":"De Keyser","year":"2014","journal-title":"Pharmacogenet Genom"},{"issue":"5","key":"10.1016\/j.ijtb.2025.07.006_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clpt.2003.12.016","article-title":"Evidence for inverse effects of OATP-C (SLC21A6) \u22175 and \u22171b haplotypes on pravastatin kinetics","volume":"75","author":"Mwinyi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ijtb.2025.07.006_bib14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2217\/pgs-2018-0166","article-title":"Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis","volume":"20","author":"Naidoo","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.ijtb.2025.07.006_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/trstmh\/trz108","article-title":"Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients","volume":"114","author":"Mukonzo","year":"2020","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.ijtb.2025.07.006_bib16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cpt.1403","article-title":"The influence of pharmacogenetic variants in HIV\/tuberculosis coinfected patients in Uganda in the SOUTH study","volume":"106","author":"Calcagno","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.ijtb.2025.07.006_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02099-17","article-title":"Effect of genetic variation of nat2 on isoniazid and slco1b1 and ces2 on rifampin pharmacokinetics in ghanaian children with tuberculosis","volume":"62","author":"Dompreh","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.ijtb.2025.07.006_bib18","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/AAC.01833-10","article-title":"The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications","volume":"55","author":"Chigutsa","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijtb.2025.07.006_bib19","first-page":"231","article-title":"A validated high-performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine","volume":"36","author":"Hemanth Kumar","year":"2004","journal-title":"Indian J Pharmacol"},{"issue":"4","key":"10.1016\/j.ijtb.2025.07.006_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/bmjgh-2018-000971","article-title":"Drug-resistant tuberculosis: is India ready for the challenge?","volume":"3","author":"Chatterjee","year":"2018","journal-title":"BMJ Glob Health"},{"issue":"6","key":"10.1016\/j.ijtb.2025.07.006_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antibiotics9060307","article-title":"Influence of single nucleotide polymorphisms on rifampin pharmacokinetics in tuberculosis patients","volume":"9","author":"Thomas","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijtb.2025.07.006_bib22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jps.20542","article-title":"Enzymes involved in the bioconversion of ester-based prodrugs","volume":"95","author":"Liederer","year":"2006","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.ijtb.2025.07.006_bib23","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.bcp.2011.08.003","article-title":"Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine","volume":"82","author":"Nakajima","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ijtb.2025.07.006_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijtb.2025.07.006_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/clpt.2013.74","article-title":"Emerging transporters of clinical importance: an update from the international transporter consortium","volume":"94","author":"Hillgren","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijtb.2025.07.006_bib26","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1124\/dmd.110.035568","article-title":"Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism","volume":"38","author":"Gao","year":"2010","journal-title":"Drug Metabol Dispos"},{"key":"10.1016\/j.ijtb.2025.07.006_bib27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00424-003-1168-y","article-title":"Organic anion transporting polypeptides of the OATP\/SLC21 family: phylogenetic classification as OATP\/SLCO super-family, new nomenclature and molecular\/functional properties","volume":"447","author":"Hagenbuch","year":"2004","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.ijtb.2025.07.006_bib28","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tube.2015.08.004","article-title":"Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters","volume":"96","author":"Te Brake","year":"2016","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijtb.2025.07.006_bib29","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s11095-009-9924-0","article-title":"The role of transporters in the pharmacokinetics of orally administered drugs","volume":"26","author":"Shugarts","year":"2009","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.ijtb.2025.07.006_bib30","first-page":"70","article-title":"Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers","volume":"5","author":"Pargal","year":"2001","journal-title":"Int J Tubercul Lung Dis"},{"issue":"3","key":"10.1016\/j.ijtb.2025.07.006_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00560384","article-title":"Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid","volume":"7","author":"Boman","year":"1974","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ijtb.2025.07.006_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00007691-198303000-00005","article-title":"Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculous patients after different rates of infusion","volume":"5","author":"Houin","year":"1983","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.ijtb.2025.07.006_bib33","first-page":"1","article-title":"Pharmacokinetic study of intravenous rifampicin","volume":"23","author":"Nitti","year":"1977","journal-title":"Pharmacology"},{"issue":"4","key":"10.1016\/j.ijtb.2025.07.006_bib34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10096-004-1109-5","article-title":"Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections","volume":"23","author":"Nuermberger","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.ijtb.2025.07.006_bib35","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/bcp.15298","article-title":"Population pharmacokinetics analyses of rifampicin in adult and children populations: a systematic review","volume":"88","author":"Muda","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ijtb.2025.07.006_bib36","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1128\/AAC.00461-07","article-title":"Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption","volume":"52","author":"Wilkins","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijtb.2025.07.006_bib37","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cpt.778","article-title":"A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses","volume":"103","author":"Svensson","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijtb.2025.07.006_bib38","doi-asserted-by":"crossref","unstructured":"Wang P, Zhang Q, Zhu Z, et al. Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant gram-negative bacterial infections. Front Pharmacol; 11.","DOI":"10.3389\/fphar.2020.00829"},{"issue":"2\u20134","key":"10.1016\/j.ijtb.2025.07.006_bib39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1515\/DMDI.2009.24.2-4.259","article-title":"Population pharmacokinetics with a very small sample size","volume":"24","author":"Mahmood","year":"2009","journal-title":"Drug Metabol Drug Interact"},{"issue":"9","key":"10.1016\/j.ijtb.2025.07.006_bib40","doi-asserted-by":"crossref","first-page":"20609","DOI":"10.3390\/ijms160920609","article-title":"SLCO1B1 c.388A>G polymorphism is associated with HDL-C levels in response to atorvastatin in chilean individuals","volume":"16","author":"Prado","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ijtb.2025.07.006_bib41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1515\/bjmg-2015-0001","article-title":"Frequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans","volume":"18","author":"Daka Grapci","year":"2015","journal-title":"Balkan J Med Genet"},{"issue":"2","key":"10.1016\/j.ijtb.2025.07.006_bib42","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cpt.1403","article-title":"The influence of pharmacogenetic variants in HIV\/tuberculosis coinfected patients in Uganda in the SOUTH study","volume":"106","author":"Calcagno","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ijtb.2025.07.006_bib43","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1128\/AAC.02307-13","article-title":"Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV","volume":"58","author":"Jeremiah","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2025.07.006_bib44","doi-asserted-by":"crossref","unstructured":"Nakai D, Nakagomi R, Furuta Y, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Therapeut; 297(3).","DOI":"10.1016\/S0022-3565(24)29609-9"},{"issue":"2","key":"10.1016\/j.ijtb.2025.07.006_bib45","first-page":"170","article-title":"Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A>G) & susceptibility in gallstone disease","volume":"129","author":"Jindal","year":"2009","journal-title":"Indian J Med Res"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001957072500174X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001957072500174X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T17:05:32Z","timestamp":1776877532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001957072500174X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S001957072500174X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2025.07.006","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifampicin population pharmacokinetics and pharmacogenomic evaluation of SLCO1B1 gene in tuberculosis patients","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2025.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Tuberculosis Association of India. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}